These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2363947)

  • 21. Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy.
    Nomura Y
    Int J Oncol; 1998 Apr; 12(4):817-24. PubMed ID: 9499441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy.
    Legha SS; Buzdar AU; Hortobagyi GN; Wiseman C; Benjamin RS; Blumenschein GR
    JAMA; 1979 Jul; 242(1):49-52. PubMed ID: 448865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
    Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
    Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
    J Clin Oncol; 1986 Feb; 4(2):186-93. PubMed ID: 2868074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
    Dowsett M; Harris AL; Smith IE; Jeffcoate SL
    Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized clinical trial to investigate the usefulness of the addition of prednisolone to tamoxifen as adjuvants to mastectomy in primary breast cancer patients with a high risk of recurrence: a preliminary report.
    DiMartino L; Demontis B; Mitchell IP; Hayward SW; Deshpande N
    Anticancer Res; 1991; 11(2):869-72. PubMed ID: 2064345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
    Langenegger T; Wahl P; Schiesser D; Thürlimann B
    Breast Cancer Res Treat; 2006 Nov; 100(2):177-81. PubMed ID: 16688477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive value of HER2 in breast cancer.
    Piccart M; Lohrisch C; Di Leo A; Larsimont D
    Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
    Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
    J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.
    Hardy JR; Powles TJ; Judson IR; Sinnett HD; Ashley SE; Coombes RC; Ellin CL
    Eur J Cancer; 1990; 26(7):824-7. PubMed ID: 2145904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
    Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC
    Lancet; 1984 Jun; 1(8391):1369-73. PubMed ID: 6145832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of metastatic breast carcinoma].
    Puglisi F; Sobrero A
    Ann Ital Chir; 1999; 70(3):377-89. PubMed ID: 10466241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen versus tamoxifen + mitoxantrone treatment in metastatic breast cancer.
    Kars A; Baltali E; Tekuzman G; Firat D; Alakavuklar M
    J Chemother; 1989 Jul; 1(4 Suppl):1196-7. PubMed ID: 16312831
    [No Abstract]   [Full Text] [Related]  

  • 36. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
    Fossati R; Confalonieri C; Torri V; Ghislandi E; Penna A; Pistotti V; Tinazzi A; Liberati A
    J Clin Oncol; 1998 Oct; 16(10):3439-60. PubMed ID: 9779724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adjuvant for breast cancer chemo-endocrine therapy].
    Taguchi T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):453-67. PubMed ID: 9530350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
    Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
    Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Endocrine therapy of recurrent breast cancer].
    Nomura Y; Tashiro H
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):421-7. PubMed ID: 3890756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.